Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook
Jan 09, 2017 12:41 pm UTC| Business
- Company Reports Preliminary Total Net Product Sales Expected to be Between$150 million and $152 million, Exceeding High End of Prior Guidance - Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER,...
Jan 09, 2017 12:31 pm UTC| Business
NEW YORK, Jan. 09, 2017 -- TG Therapeutics, Inc.(NASDAQ:TGTX) today announced that theU.S. Food and Drug Administration(FDA) has granted orphan drug designation covering the combination of TG-1101 (ublituximab), the...
Jan 09, 2017 12:31 pm UTC| Business
NEW YORK, Jan. 09, 2017 -- TG Therapeutics, Inc.(NASDAQ:TGTX) today announced that theU.S. Food and Drug Administration(FDA) has granted orphan drug designation covering the combination of TG-1101 (ublituximab), the...
Jan 09, 2017 12:31 pm UTC| Business
- Enasidenib (AG-221) NDA Submitted for IDH2m Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - - AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017 - - AG-348 Advancing to Pivotal Development in PK...
Jan 09, 2017 12:31 pm UTC| Business
- Enasidenib (AG-221) NDA Submitted for IDH2m Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - - AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017 - - AG-348 Advancing to Pivotal Development in PK...
Jan 09, 2017 12:31 pm UTC| Business
RICHMOND, Calif., Jan. 09, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, announced today that it recognized revenue from the sale of 16 Ekso GT systems in the fourth quarter ended...
Jan 09, 2017 12:31 pm UTC| Business
RICHMOND, Calif., Jan. 09, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, announced today that it recognized revenue from the sale of 16 Ekso GT systems in the fourth quarter ended...